Navigation Links
Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
Date:2/9/2010

CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction.  The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old.  The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.

Palatin anticipates completing the study in the current calendar quarter, with data analysis completed in the next calendar quarter.

"The current study is designed to validate our hypothesis that increases in blood pressure and gastrointestinal events seen with intranasally administered bremelanotide were primarily related to high intranasal absorption in a subset of patients. The results from this study in the male demographic we are targeting for commercialization, combined with results from our study reported last August, are intended to further address concerns raised by the Food and Drug Administration," said Trevor Hallam, Ph.D., Executive Vice President of Research and Development of Palatin.

Data from this study will be submitted to the Food and Drug Administration.  Palatin intends to initiate a Phase 2, at-home, study of subcutaneous bremelanotide in men with erectile dysfunction who are not responsive to therapies with drugs such as Viagra®, a brand of sildenafil citrate, in the second half of this calendar year.  The Phase 2 bremelanotide erectile dysfunction program is designed to provide the data required to initiate Phase 3 registrati
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Palatin Technologies to Present at 8th Annual BIO Investor Forum
2. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
5. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
6. Wound Management Technologies, Inc. Engages Miller Tabak, A National Investment Banking Firm Specializing in the Healthcare Market Space
7. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
8. AVAX Technologies, Inc. Closes Bridge Financing
9. Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging
10. Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up
11. Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , August 27, 2015 ... convened in Boston on July ... in an effort to more fully exploit the potential ... applied to brain diseases. "As an established ... a responsibility to assume a leadership role - in ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, Inc., ... treatment of cancer, today announced that Rachel ... company,s Board of Directors, has been appointed chief ... Eli Lilly and AstraZeneca, and also oversaw clinical ... checkpoint inhibitor, at Bristol-Myers Squibb and the development ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015 Oryzon today ... Renshaw 17th Annual Global Investment Conference in New ... ORYZON will be represented by President and CEO Carlos ... Dr. Buesa will present this information on Thursday September 10, ... Floor).  The company is completing preclinical development of its ORY-2001 ...
Breaking Medicine Technology:New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4
... to Educate Women About this Common Condition, MILWAUKEE, ... at the Hyatt Regency Milwaukee hotel (333 West Kilbourn ... 7:30 pm to talk about her,experience with stress urinary ... Down There?: Breaking the Ice About SUI, a,national public ...
... Opiate-Like Side Effects For Several ... Months Following a Single Administration, SOUTH SAN FRANCISCO, Calif., ... that it has initiated a new,Phase 2 study of Adlea(TM) ... total knee replacement surgery, also called,total knee arthroplasty (TKA). Adlea ...
Cached Medicine Technology:Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee 2Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee 3Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 2Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 3Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 4
(Date:8/27/2015)... Los Angeles, CA (PRWEB) , ... August 27, 2015 , ... ... suggests that the helpfulness of a doctor is tied directly to the success of ... obese patients over a two year period, measured their weight loss over that period, ...
(Date:8/27/2015)... ... 27, 2015 , ... Workflow in labs has greatly benefitted ... in the last decade. New features such as multiplexing, microfluidics, and integration with ... do lab managers, technicians, and researchers find handy metrics to compare and judge ...
(Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. ... Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at the Marriott DTC, ... outlets as health authorities, and will present a two part seminar entitled, “How to ...
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 ... slammed into the Gulf Coast, killing more than 1,800 people, displacing hundreds of ... a Georgia State University study. , While most people don’t develop persistent depression ...
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a leading provider of ... is ICD-10 ready and available to all clients. All Krames Patient Education content ... are more targeted and return a more comprehensive data set of content than ...
Breaking Medicine News(10 mins):Health News:Article on Physician Influence on Weight Loss Highlights the Importance of a Doctor Who Cares, says Dr. Feiz & Associates 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3
... type of anti-inflammatory drugs could be better for older ... older people to relieve arthritis symptoms. The problem is ... gastrointestinal problems. A specialized group of NSAIDs called COX-2 ... with heart complications. ,Researchers looked more closely at ...
... smoking actually helps arteries stay open following a procedure ... who conducted the study say they do not recommend ... of carbon monoxide in the blood stream may be ... ,Peripheral artery disease(PAD) is a narrowing or blockage ...
... level is a marker to help determine if a man ... prevalence of men with prostate cancer who had a PSA ... the Prostate Cancer Prevention Trial. Among 9,459 men in the ... than four or an abnormal rectal examination. For this research, ...
... shows pregnant women with asthma can reduce their risk of ... // mothers who ate oily fish, such as salmon and ... children with asthma. In fact, researchers say the more oily ... to develop asthma. Children with non-asthmatic mothers did not benefit ...
... recent study researchers say, the ancient Eastern tradition of yoga ... part in yoga classes reported better sleep quality than those ... 39 lymphoma patients who were either undergoing treatment or who ... patients were assigned to the yoga classes while the other ...
... one of the most worrisome long-term side effects of high-dose ... identify biochemical markers that might indicate which patients are at ... ,Troponin I is a protein present only in ... heart muscle injury that is used to diagnose and treat ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: